The dominant theory in economics for centuries in the Western world has been the free market system, yet the ability of competitive markets to provide quality care has been a central point of recent debate. Extensive government regulation, though well-intentioned, adversely affects the overall health of Americans, inhibits medical innovation, and demands enormous tax-payer investment. The Initiative on Enabling Choice and Competition in Healthcare delivers cutting edge research on the efficiencies of competitiveness in the healthcare sector to demonstrate that free market forces can and do work to provide innovative, equitable, and high-quality care.
Our Vision
To be the leading university-based research center in free-market healthcare, promoting choice and competition to ensure greater access to existing care and new innovations.
Our Mission
To conduct evidence-based research and analyses on market-based choice and competition in the healthcare sector to lead to better-informed policy recommendations.
Working Papers
International Comparison for Drug Prescription Prices
This white paper is based on the Policy Brief: International Price Differences for Drug Prescriptions. The National Review also featured Professor Philipson's oped on the same topic. Many international drug price comparisons conclude that the U.S. has the highest...
COVID-19 Biopharmaceutical Innovation and Industry Appropriation
The rapid emergence of vaccines and therapeutics in response to the onset of the coronavirus (COVID-19) pandemic demonstrated the value of medical innovation. These advances not only led to enhanced patient welfare by reducing the disease’s mortality and morbidity but...
Policy Brief: The Impact of Price Setting at 9 Years on Small Molecule Innovation Under the Inflation Reduction Act
This policy brief provides a quantitative analysis of how the Inflation Reduction Act’s (IRA) policy to set prices for select small molecule drugs 9 years after FDA approval impacts innovation and patient health. Price setting under the IRA undermines existing...
Learn more about Operation Warp Speed:
In the Press
Drugs Are Cheaper Here Than Abroad, and Other Countries Should Adopt Our Model
By Prof. Em. Tomas J. Philipson Not vice versa. Conventional wisdom holds that prices for prescription drugs paid by our government are...
International Comparison for Drug Prescription Prices
This white paper is based on the Policy Brief: International Price Differences for Drug Prescriptions. The National Review also featured Professor...
Policy Brief: International Price Differences for Drug Prescriptions
This policy brief presents a quantitative analysis of the price of drug prescriptions filled in the United States compared to other developed...
2024 ECCHC Supply-Side Economics in Healthcare Conference – Watch Now!
The 2024 ECCHC Supply-side Economics in Healthcare Conference convened both in-person and virtually on Friday, May 3. Watch the full conference, or individual presentations and learn more about the conference here!